Annovis Bio Inc
NYSE:ANVS
Annovis Bio Inc
NYSE:ANVS
Price:
5.9195 USD
-3.12%
Updated:
May 2, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of ANVS.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ANVS
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
ANVS Competitors Multiples
Annovis Bio Inc Competitors
Annovis Bio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Annovis Bio Inc
NYSE:ANVS
|
62.3m USD | 0 | -1.1 | -1.3 | -1.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | 58.6 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | 28.6 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.6 | 25.4 | 16.9 | 18.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.3B USD | 3 | 168.2 | 6.7 | 8.8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.6 | -9.6 | -10.4 | -8.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 26.8 | 13.8 | 17.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
